层连蛋白受体67LR在胶质瘤细胞增殖中作用的研究

脑胶质瘤是颅内常见恶性肿瘤,常规的治疗手段很难将其完全治愈.67 kD层连蛋白受体(67 kDlaminin receptor,67LR)属于高亲和,非整联蛋白家族成员,试验表明,该蛋白在许多癌细胞表面过量表达,并且其表达水平与肿瘤细胞的粘附、增殖、分化、迁移、信号转导及转移能力密切相关.本试验利用shRNA干扰、RT-PCR、免疫细胞化学和MTT等技术通过下调67LR基因的表达来探讨其在胶质瘤细胞中的表达情况,及其对胶质瘤细胞增殖能力的影响.结果发现,相对于正常脑组织,67LR在脑胶质瘤细胞表面大量表达.采用shRNA下调其表达后发现胶质瘤细胞的增殖能力明显降低.结果表明,67LR在胶质瘤细胞表面的过表达与此细胞的增殖能力呈明显相关.     

CDA-2 induces differentiation and inhibits proliferation of human SWO-38 glioma cells

AIM: To investigate the differentiation-inducing effect of cell differentiation agent-2 (CDA-2) in human SWO-38 glioma cell line in vitro.METHODS: The inhibitory effect of CDA-2 on cell proliferation was assessed by MTT assay and colony formation assay.Cell morphology was determinded by light microscopy observation,and the expression of GFAP (glial fibrillary acidic protein) was detected by immunohistochemistry and Western blotting.Western blotting was also applied to explore the expression of PPARγ and COX-2.RESULTS: The data showed that CDA-2 inhibited proliferation and induced differentiation of SWO-38 cells.The inhibition efficiency was time-dependent and dose-dependent .The IC₅₀ of CDA-2 was (2.33±0.37) g/L and (0.51±0.01) g/L,respectively when cells were treated for 72 h and 10 days.CDA-2 caused differentiation of human glioma cells as indicated by outgrowth of long processes and expression of astrocyte marker GFAP.Simultaneously,the expression of PPARγ increased after 3 h of CDA-2 treatment，while the expression of COX-2 decreased after 48 h of CDA-2 treatment.CONCLUSION: CDA-2 inhibits proliferation and induces differentiation of SWO-38 cells.These effects may be through increasing cellular GFAP,PPARγ level and decreasing COX-2 expression induced by CDA-2.     

4E-BP1 regulates sensitivity of human glioma cells to carmustine

AIM：For finding new target to overcome acquired drug resistance of glioma, the relationship between eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and acquired drug resistance to carmustine ［1,3-bis(2-chloroethyl)-1-nitrosourea,BCNU］ in human glioma cells was investigated. METHODS：Western blotting was used to analyze the expression levels of 4E-BP1 and phosphorylated 4E-BP1 （p-4E-BP1） in SWOZ2 cells and BCNU-resistant SWOZ2 (SWOZ2-BCNU) cells. The siRNA targeting to human 4E-BP1 mRNA was transfected into SWOZ2 cells. Cell counting kit-8 was used to detect the sensitivity of the cells to BCNU before and after transfection. The location of 4E-BP1 and p-4E-BP1(T70) in SWOZ2 cells and SWOZ2-BCNU cells was observed by the method of immunofluorescence. RESULTS：The expression of 4E-BP1 in SWOZ2-BCNU cells was significantly lower than that in SWOZ2 cells. Down-regulation of 4E-BP1 expression in SWOZ2 cells decreased the sensitivity of the cells to BCNU. The expression of p-4E-BP1(T70) in the nucleus of SWOZ2-BCNU cells was significantly higher than that in the cytosol. CONCLUSION：4E-BP1 is involved in human glioma acquired drug resistance as a translation key protein.     

Effect of sorcin expression on sensitivity of human glioma cells to cisplatin

AIM：To investigate the effect of sorcin expression on the sensitivity of human glioma cells to cisplatin. METHODS：pSilencerTM 3.1-H1-sorcin siRNA recombinant plasmid was constructed, and transfected into human glioma U251 cells. RT-PCR and Western blotting were used to analyze the expression of sorcin at mRNA and protein levels after transfection. The viability of U251 cells was measured by MTT assay. The protein expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) in U251 cells was detected by Western blotting. RESULTS：The plasmid pSilencerTM 3.1-H1-sorcin siRNA was successfully constructed, and was confirmed by restriction enzyme digestion and sequence analysis. The expression of sorcin at mRNA and protein levels was significantly decreased after sorcin siRNA was transfected into U251 cells (P<0.05). Inhibition of sorcin expression significantly decreased the viability of U251 cells treated with cisplatin (P<0.05), and the expression of P-gp and MRP1 proteins was also inhibited (P<0.05). CONCLUSION：Inhibition of sorcin expression increases the sensitivity of U251 cells to cisplatin by decreasing the expression of resistance-related proteins P-gp and MRP1, suggesting that sorcin may be associated with the resistance of glioma cells to cisplatin.     

Cholestane-3β, 5α, 6β-triol induces apoptosis of malignant glioma cells

AIM：To investigate the effect of cholestane-3β, 5α, 6β-triol (Triol) on apoptosis of malignant glioma cells. METHODS：C6 cells and A172 cells were incubated with Triol at different concentrations for different time durations. MTT assay was used to detect the cell viability. Hoechst 3f3342 staining and TUNEL assay were used to analyze the cell apoptosis. The caspase activity was measured. The expression of apoptosis-related proteins, Bcl-2 family members, was determined by Western blotting. RESULTS：Triol decreased the cell viability of C6 and A172 cells in a dose- and time-dependent manner and the IC50 values were (17.8±0.6)μmol/L and (20.6±0.2) μmol/L, respectively. Visible nuclei with apoptotic characteristics, significant increase in TUNEL-positive cells, and the activation of apoptotic execution enzyme caspase-3 indicated that cell apoptosis was induced by Triol in both cell lines. After C6 cells were exposed to Triol for 12 h, 24 h and 48 h, the activity of caspase-8 in extrinsic apoptotic pathway and caspase-9 in intrinsic apoptotic pathway was increased time-dependently. Meanwhile, the levels of anti-apoptotic proteins, Bcl-2 and Bcl-xL, was down-regulated, while pro-apoptotic protein Bak was up-regulated in a time-dependent manner. CONCLUSION：Triol induces apoptosis of malignant glioma cells by activating intrinsic and extrinsic apoptotic pathways, and Bcl-2 family members are involved in Triol-induced apoptosis.